Related Experiment Videos
A new biological matrix for septal occlusion
Christian Jux1, Peter Wohlsein, Michael Bruegmann
1Department of Pediatric Cardiology and Pediatric Intensive Care Medicine, Hannover Medical School, Hannover, Germany.
Journal of Interventional Cardiology
|May 29, 2003
Summary
New intestinal collagen layer (ICL) septal occluders demonstrated superior biocompatibility in lamb models. These bioengineered collagen scaffolds promoted faster healing and reduced complications compared to traditional polyester devices.
Area of Science:
- Biomaterials Science
- Cardiovascular Research
- Regenerative Medicine
Background:
- Ideal septal occluder scaffolds require excellent biocompatibility for optimal healing and resorption.
- Intestinal collagen layer (ICL) is a bioengineered type-1 collagen from porcine submucosa, designed for gradual host tissue replacement.
Purpose of the Study:
- To evaluate the biocompatibility and healing response of CardioSEAL occluders modified with an intestinal collagen layer (ICL) compared to standard polyester scaffolds.
- To assess the in vivo performance of ICL-modified occluders in a lamb model for atrial septal defect closure.
Main Methods:
- Modification of CardioSEAL occluders by replacing polyester fabric with an intestinal collagen layer (ICL).
- Percutaneous transcatheter closure of atrial septal defects in lambs using ICL-modified and standard occluders.
- Pathomorphological and histological investigation at 2, 4, and 12 weeks post-implantation.
Main Results:
- ICL devices achieved complete neo-endothelial coverage within 2 weeks, showing quicker endothelialization than controls.
- Histology revealed decreased thrombogenicity and superior biocompatibility with minimal cellular infiltration for ICL scaffolds.
- After 3 months, ICLs remained intact but showed initial signs of disintegration, resorption, and remodeling.
Conclusions:
- Short-term in vivo results indicate excellent biocompatibility of bioengineered collagen matrix scaffolds.
- ICL-modified occluders offer improved outcomes, including faster endothelialization, reduced thrombogenicity, and a decreased host immunological response.